Vitaliy Katsenelson Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. Vitaliy Katsenelson December 17, 2025